Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2a, First-in-human, Open-label, Dose-escalating Study With a Safety Expansion Cohort to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Anti-tumour Activity of TAX2 in Patients With Relapsed/Refractory Advanced/Metastatic Solid Tumours

NCT07688148 is registered in ClinicalTrials.gov with Apmonia Therapeutics as lead sponsor.

NCT NCT07688148
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07688148 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2a, First-in-human, Open-label, Dose-escalating Study With a Safety Expansion Cohort to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Anti-tumour Activity of TAX2 in Patients With Relapsed/Refractory Advanced/Metastatic Solid Tumours
Lead sponsor
Apmonia Therapeutics
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
October 31, 2026
Completion date
August 31, 2030
Enrollment
48 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor cancers